Giant duodenal ulcer: the hepatic intra-arterial chemotherapy variant

Eran Goldin, Tamar Peretz and Eugene Libson

Departments of 1Gastroenterology, 2Radiation and Clinical Oncology and 3Radiology, Hadassah University Hospital, Hebrew University-Hadassah Medical School, IL-91120 Jerusalem, Israel.

Summary: Giant duodenal ulcers are extensive ulcers, more than 2.5 cm in diameter, that involve a large portion of the duodenal bulb. These atypical duodenal ulcers create serious problems to the patient and the physician, are frequently complicated by bleeding and penetration, and have a high mortality rate. Most of the reported cases were classified as a severe variant of the common peptic ulcer disease, others were associated with the Zollinger Ellison syndrome. We report here four patients with giant duodenal ulcers but with a different and definitive aetiology: hepatic intra-arterial chemotherapy infusion for liver metastases or primary hepatocellular carcinoma.

Introduction

Giant duodenal ulcer is considered an atypical and dangerous variant of peptic ulcer disease. The diagnostic criteria are the extension of the ulcer – more than 2.5 cm in diameter – and the fact that about 80% of the bulb is involved in the ulcer cavity, predisposing to haemorrhage or perforation.

In the pre-endoscopic era, some cases were misdiagnosed by upper gastrointestinal X-ray series and confused with deformed bulbs or pseudodiverticula. Today, combined X-ray and endoscopic studies make the diagnosis easier.

Treatment of liver metastases with hepatic intra-arterial chemotherapy (HAIC), using a surgically implantable pump, has become a widespread method and was associated with improved clinical responses and survival. However, several gastrointestinal complications have been reported: erosions and ulcers in stomach and duodenum, biliary sclerosis and acalculous acute cholecystitis.

We describe four non-peptic patients who received intra-arterial chemotherapy for liver metastases and who developed giant duodenal ulcers. Two of them died from severe gastrointestinal bleeding. We discuss this new aetiology for giant duodenal ulcers and stress the importance of a closer endoscopic follow-up of patients undergoing intra-arterial cytotoxic treatment for early detection of gastrointestinal damage.

Materials and methods

During the period from July 1982 to December 1986, 23 patients (18 with liver metastases and 5 with primary hepatocellular carcinoma) were treated in our hospital by a selective infusion of chemotherapeutic agents through a surgically implanted hepatic artery catheter and pump. None of them had a history of peptic ulcer. During laparotomy, the gastroduodenal artery and the right gastric artery were ligated to avoid perfusion of the stomach. The drugs we used were fluorouridine (FUDR) by continuous infusion in combination with intra-arterial mitomycin-C bolus. Patients with primary hepatocellular carcinoma received a bolus of Adriamycin instead of mitomycin-C. The patients were followed up and if any gastrointestinal complaints or symptoms appeared a gastroscopy or X-ray series was performed.

Results

Ten patients experienced gastrointestinal problems or liver function disorders and underwent gastroscopy, upper X-ray studies or endoscopic retrograde cholangiography. In four of these patients, a giant duodenal ulcer was found. In two patients biliary sclerosis was diagnosed and in the others a moderate erosive duodenitis was disclosed by endoscopy. A clinical description of the patients with giant duodenal ulcer is presented in Table I.

Correspondence: E. Goldin M.D.
Accepted: 9 December 1987

© The Fellowship of Postgraduate Medicine, 1988
Table I  Clinical details in giant duodenal ulcer patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Liver irradiation</th>
<th>HAIC</th>
<th>Time from initial infusion to symptoms</th>
<th>Gastrointestinal symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>41</td>
<td>F</td>
<td>Breast carcinoma Liver metastases</td>
<td>2000 rad</td>
<td>Mitomycin-C FUDR</td>
<td>5 months</td>
<td>Epigastric pains</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>F</td>
<td>Colon carcinoma Liver metastases</td>
<td>2000 rad</td>
<td>Mitomycin-C FUDR</td>
<td>6 months</td>
<td>Bleeding</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>M</td>
<td>Primary hepatocellular carcinoma</td>
<td>None</td>
<td>FUDR Adriamycin</td>
<td>5 months</td>
<td>Bleeding</td>
</tr>
<tr>
<td>4</td>
<td>74</td>
<td>M</td>
<td>Primary hepatocellular carcinoma</td>
<td>None</td>
<td>FUDR Adriamycin</td>
<td>7 months</td>
<td>Bleeding</td>
</tr>
</tbody>
</table>

HAIC = hepatic intra-arterial chemotherapy; FUDR = 5-flourouracil.

They were two female patients with liver metastases (primaries: colon and breast) who were treated by liver irradiation (2000 rad) and received mitomycin-C and FUDR by HAIC; and two male patients with primary hepatocellular carcinoma who received FUDR and adriamycin through the intra-arterial pump. The interval between the initial dose of chemotherapy and the development of symptoms was variable, ranging from 5 to 7 months. The presenting symptom in three of the patients was upper gastrointestinal bleeding and in the remaining patient epigastric pain. Figure 1 shows an upper gastrointestinal X-ray of giant duodenal ulcer in patient no. 3. In all the patients, when the ulcer was diagnosed, chemotherapy was discontinued and anti-ulcer therapy with \( H_2 \) blockers and sucralfate instituted.

Patients 3 and 4 died with severe bleeding 2 and 3 weeks after the diagnosis. Patients 1 and 2 stopped bleeding, the giant ulcer healed and they died 4 and 6 months later from reasons unrelated to this complication.

Discussion

Giant duodenal ulcers measure more than 2.5 cm in diameter. Usually they are on the posterior wall and are frequently complicated by bleeding and penetration. Also gastric outlet obstruction may occur.

Usually, giant duodenal ulcer is diagnosed after a long, typical, duodenal ulcer disease history, and till now was considered as a severe variant of common peptic ulcer disease. In Zollinger Ellison syndrome, some cases of giant duodenal ulcer were reported. One case was attributed to non-steroidal anti-inflammatory drug ingestion.

We report here four cases of giant duodenal ulcer in patients receiving intra-arterial chemotherapy for liver metastases or primary hepatocellular carcinoma. This treatment, using a percutaneous catheter or a surgically implanted hepatic artery catheter and a pump, was associated with a response rate of 55–83%. Gastrointestinal complications had been described and included gastroduodenal ulceration, biliary sclerosis and acalculous cholecystitis. Giant duodenal ulcer was a frequent complication in our patients. We found only one clear description of a giant duodenal ulcer in previous publications.

One explanation for these serious problems is an unavoidable infusion of the stomach and the duodenum via the gastroduodenal and right gastric arteries. On the other hand, when these arteries are ligated during laparotomy, as we did, a relative ischaemia may also cause damage of the mucosa. Another contributing factor could be the local perfusion of the duodenum by the drugs secreted through the hepatobiliary tract.

In our series, we found that the most acute, life-threatening gastrointestinal complication of the
selective intra-arterial chemotherapy is giant duodenal ulcer. Two of our four patients with this complication died with massive bleeding. It is of interest that these two cases were primary hepatocellular carcinoma patients. Patt et al. reported selective intra-arterial infusion in this kind of patient, but did not describe such complications.

We conclude that giant duodenal ulcer may be induced in non-peptic patients by selective intra-arterial infusion of chemotherapy for liver metastases. We stress the high mortality rate of this condition and recommend endoscopy before and after treatment, even in asymptomatic patients or those with mild, non-specific abdominal complaints.

References

Giant duodenal ulcer: the hepatic intra-arterial chemotherapy variant.
E. Goldin, T. Peretz and E. Libson

doi: 10.1136/pgmj.64.752.431

Updated information and services can be found at:
http://pmj.bmj.com/content/64/752/431

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/